Allergan ruling casts doubt on tribal patent strategy

(Reuters) – A U.S. judge’s ruling on Monday invalidating Allergan Plc’s patents on its blockbuster $ 1.5 billion dry-eye medicine, Restasis, has cast doubt on the company’s novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.


Reuters: Health News